Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on June 7, 2016. The filing addresses Item 5.02 regarding the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. The report details compensation adjustments and equity awards approved by the Compensation Committee for fiscal year 2016.
Key Financial Metrics and Compensation Details
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. Instead, it discloses specific executive compensation figures approved on June 7, 2016:
- Phillip P. Chan, MD, PhD (CEO): Base salary of $350,000 (approx. 8% increase effective Jan 1, 2016); 97,000 stock options; 26,000 bonus restricted stock units (RSUs); 57,000 change in control RSUs.
- Vincent J. Capponi (COO): Base salary of $291,000 (approx. 8% increase effective Jan 1, 2016); 91,500 stock options; 23,000 bonus RSUs; 54,000 change in control RSUs.
- Kathleen P. Bloch (CFO): Base salary of $255,000 (approx. 8% increase effective Jan 1, 2016); 77,500 stock options; 21,000 bonus RSUs; 47,000 change in control RSUs.
- Robert H. Bartlett, MD (CMO): No base salary; paid consulting fees of $54,000 annually; 20,000 stock options.
Stock options have a strike price of $4.69 and a 10-year term. Bonus RSUs vest over three years based on continued service. Performance-based stock options vest upon achieving specific milestones including revenue targets, financing proceeds, clinical study completion, and strategic partnerships.
Material Changes Versus Prior Period
The primary material change reported is the approval of an 8% increase in annual base salaries for the CEO, COO, and CFO, effective January 1, 2016. Additionally, the Board approved an amendment to the Company's 2014 Long-Term Incentive Plan to increase the number of authorized shares by 700,000. This amendment was necessary because the available shares were insufficient to award all employees following the 2016 annual grants.
Guidance, Outlook, and Risks
The filing outlines specific performance milestones required for the vesting of stock options, which serve as implicit operational targets:
- Revenue and Expense: 30% of options vest upon achieving 2016 budgeted gross revenues (minimum 90% achievement) and maintaining operating expenses within the approved budget ratio.
- Financing: 25% of options vest upon consummating equity or debt financing with minimum gross proceeds of $10,000,000.
- Clinical and Regulatory: 40% of options vest upon successful completion of the REFRESH 1 clinical study, FDA approval of a product candidate, and publication of at least two clinical studies.
- Strategic: 5% of options vest upon achieving new material strategic partnerships or significant territory expansion.
Contingencies: The amendment to the Incentive Plan increasing authorized shares by 700,000 is subject to stockholder approval. The Company anticipates further amending the Plan at the 2017 Annual Meeting of Stockholders.
Investor Verification Checklist
- Verify the stockholder approval status of the 700,000 share increase to the 2014 Long-Term Incentive Plan.
- Monitor progress toward the $10,000,000 financing milestone required for option vesting.
- Track the status of the REFRESH 1 clinical study and FDA approval timelines for product candidates.
- Confirm the actual 2016 gross revenue and operating expense ratios against the budgeted figures to assess vesting eligibility.
- Review the Company's 2017 Annual Meeting agenda for proposed further amendments to the Incentive Plan.